Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Carpiniello

Surgery New York, NY Medical Doctor

NPI 1932595840 CMS profile 5162471

425 W 59Th St Fl 7, New York, NY 10019

Open in the dashboard

General payments

$10,730

94 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Carpiniello of New York, NY is reported in the CMS Open Payments database as having received $10,730 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,314 30
2024 General $855 15
2023 General $1,502 16
2022 General $6,492 20
2021 General $254 5
2020 General $109 6
2019 General $203 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Carpiniello
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Matthew Carpiniello were reported at $1,314. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Matthew Carpiniello Surgery median Middle half National median
2019 $203 $253 $82–$1,521 $163
2020 $109 $131 $40–$706 $114
2021 $254 $168 $50–$904 $132
2022 $6,492 $224 $76–$1,218 $149
2023 $1,502 $253 $82–$1,255 $160
2024 $855 $279 $90–$1,381 $164
2025 $1,314 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,468 16 payments
  2. Boston Scientific Corporation $877 15 payments
  3. Inari Medical, Inc. $757 11 payments
  4. W. L. Gore & Associates, Inc. $661 5 payments
  5. Penumbra, Inc. $542 6 payments
  6. Stryker Corporation $433 13 payments
  7. Becton, Dickinson and Company $203 2 payments
  8. Cook Medical LLC $140 2 payments
  9. Janssen Pharmaceuticals, Inc $125 7 payments
  10. Silk Road Medical, Inc. $122 1 payment
  11. Other $400 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,730 93 payments
  2. Grant $5,000 1 payment
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $6,462 15 payments
  2. FLOWTRIEVER CATHETER, S $963 15 payments
  3. CT THROMBECTOMY SYSTEM KIT $963 15 payments
  4. GORE VIABAHN VBX Balloon Expandable Endo $647 4 payments
  5. Indigo System $386 4 payments
  6. General - Vascular Intervention $340 6 payments
  7. FLOWTRIEVER $227 9 payments
  8. ELUVIA $169 1 payment
  9. RUBY Coil $142 1 payment
  10. COOK $140 2 payments
  11. Other $1,437 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

123

Median for Vascular Surgery: 122

Drug cost

$17,678

Median for Vascular Surgery: $14,135

Branded share of claims

44.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 18 $10,043
Xarelto Rivaroxaban Brand 12 $6,656
Cilostazol Generic 26 $662
Clopidogrel Clopidogrel Bisulfate Brand 25 $143
Oxycodone Hcl Generic 30 $89
Atorvastatin Calcium Generic 12 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$432,265

Of which drugs: $566

Medicare patients

528

Average age 76

Services billed

7,007

229 women, 299 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Chronic kidney disease 58%
Arthritis 57%
Ischemic heart disease 56%
Heart failure 48%
COPD 35%
Atrial fibrillation 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 80 5,400 $565

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record